The Female Hypoactive Sexual Desire Disorder drugs in development market research report provides comprehensive information on the therapeutics under development for Female Hypoactive Sexual Desire Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Female Hypoactive Sexual Desire Disorder. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Female Hypoactive Sexual Desire Disorder and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Female Hypoactive Sexual Desire Disorder by eight companies/universities/institutes. The top development phase for Female Hypoactive Sexual Desire Disorder is phase ii with four drugs in that stage. The Female Hypoactive Sexual Desire Disorder pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Female Hypoactive Sexual Desire Disorder pipeline products market are: Freya Pharma Solutions, Kuhnil Pharmaceutical and Shanghai Fosun Pharmaceutical (Group).

The key targets in the Female Hypoactive Sexual Desire Disorder pipeline products market include Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR), cGMP Specific 3′,5′ Cyclic Phosphodiesterase (cGMP Binding cGMP Specific Phosphodiesterase or PDE5 or PDE5A or EC 3.1.4.35), and 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A).

The key mechanisms of action in the Female Hypoactive Sexual Desire Disorder pipeline product include Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR) Agonist with four drugs in Phase III. The Female Hypoactive Sexual Desire Disorder pipeline products include seven routes of administration with the top ROA being Oral and two key molecule types in the Female Hypoactive Sexual Desire Disorder pipeline products market including Small Molecule, and Synthetic Peptide.

Female Hypoactive Sexual Desire Disorder overview

Hypoactive sexual desire disorder (HSDD) is an absence of sexual fantasies and desire for sexual activity. The predisposing factors include anxiety, depression, androgen deficiencies, and chronic debilitating illnesses such as chronic renal failure, hyper-prolactinaemia, and hypo-hyperthyroid states. Treatment includes antidepressant and hormone therapy.

For a complete picture of Female Hypoactive Sexual Desire Disorder’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.